Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127373 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TSHRMAPK1OPRM1TRPV1 | |
| SCHEMBL1127822 | 0.91 | ALDH1A1 (0.39) | ALDH1A1TSHRMAPK1OPRM1LMNA | |
| SCHEMBL1127741 | 0.91 | ALDH1A1 (0.39) | ALDH1A1TSHRMAPK1OPRM1LMNA | |
| Bicarbonate SCHEMBL3813582 | 0.88 | GABRP (0.38) | ALDH1A1TSHRMAPK1OPRM1 | |
| SCHEMBL829502 | 0.84 | TRPV1 (0.41) | ALDH1A1TSHRMAPK1OPRM1TRPV1 | |
| SCHEMBL23028519 | 0.81 | ALDH1A1 (0.39) | ALDH1A1TSHRMAPK1OPRM1TRPV1 | |
| SCHEMBL28643674 | 0.80 | OPRM1 (0.55) | ALDH1A1TSHRMAPK1OPRM1TRPV1 | |
| SCHEMBL17143544 | 0.80 | — | — | |
| SCHEMBL3366461 | 0.79 | OPRM1 (0.61) | OPRM1LMNASPHK1 | |
| SCHEMBL16240597 | 0.78 | ALDH1A1 (0.41) | ALDH1A1TSHRMAPK1OPRM1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
| EP-2282981-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141090-A9 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009141090-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | GLUL, GATD3, QPCT | ALDH1A1 1003/4885TSHR 2389/4885MAPK1 2822/4885 |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | GLUL, GATD3, QPCT | ALDH1A1 814/4885TSHR 2819/4885MAPK1 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.